By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more ...
Ultimately, González was diagnosed with silicosis, a distinct form of pulmonary fibrosis, or severe lung scarring. Silicosis ...
Even after completing treatment for tuberculosis (TB), some patients may remain vulnerable to further lung infections.
Adding fan-to-face therapy to a supervised exercise training program lowers exertional breathlessness across training ...
As the nation recognizes Women’s History Month, Illinois health leaders have launched a renewed, statewide effort to increase ...
While smoking remains the leading risk factor, other contributors include secondhand smoke, air pollution, radon exposure and ...
Clinical Trials Arena on MSN
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success
The biopharma company will now seek Arikayce’s approval in the US and Japan for use in earlier lines of treatment.
As more states legalize marijuana, many people might be wondering if that means it is safe to use. While smoking tobacco is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results